Background Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) among young individuals and ...

Please provide your email address to receive an email when new articles are posted on . Aficamten improved peak oxygen uptake at 24 weeks vs. metoprolol in patients with obstructive hypertrophic ...

Final Decision from European Commission Expected in Q1 2026SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- Cytokinetics, ...

Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten did not improve outcomes vs. placebo at 48 weeks in patients with nonobstructive hypertrophic ...

In one of two trials that substantially expand clinical evidence with myosin inhibitors in the treatment of hypertrophic cardiomyopathy (HCM), a next-in-class agent beat beta-blockers in first-line ...

Hypertrophic cardiomyopathy (HCM) is a common heart disease that causes the heart muscle to thicken, sometimes to the point ...

Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon ...

The hearts of people with hypertrophic cardiomyopathy are thicker, and must beat more forcefully to pump out blood into the body. This can lead to a variety of symptoms, which may appear only ...